Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific, Middle East and Africa: 2,207 cases from 44 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- Anonymised companies €221.6m 39 % · 45 cases
- Becton, Dickinson and Company (BD) €166.7m 30 % · 1 case
- Access DX Laboratory, LLC €31.7m 6 % · 1 case
- Advanced Pathology Solutions PLLC und APS MSO LLC €25.9m 5 % · 1 case
- C.R. Bard, Inc.; Liberator Medical Supply, Inc.; Liberator Holdings; Rochester Medical Corporation €16.3m 3 % · 1 case
- NUWAY Alliance, Inc. €15.8m 3 % · 1 case
- Medirex s. r. o.; KLINICKÁ BIOCHÉMIA s.r.o.; Unilabs Slovensko, s. r. o.; synlab slovakia s. r. o.; Asociácia laboratórií €14.6m 3 % · 1 case
- Oroville Hospital €9.77m 2 % · 1 case
- NeoGenomics Laboratories Inc. €8.59m 2 % · 1 case
- PHOENIX Zdravotnícke zásobovanie, a.s.; TRANSMEDIC SLOVAKIA, s.r.o. (in Konkurs) €7.8m 1 % · 1 case
- 35 more€46.1m
When?
per year, by date of decision| Period | Cases | Total |
|---|---|---|
| 2024 | 1 | €166.7m |
| 2025 | 0 | – |
| 2026 | 0 | – |
1 case
16 Dec 2024 Becton, Dickinson and Company (BD)Becton Dickinson: risks of Alaris infusion pump concealed – 175 million USD €166.7m
The medical technology manufacturer misled investors about regulatory risks of the Alaris infusion pump, which had more than 25 software defects, and did not record the remediation costs, as a result of which operating income in the fourth quarter of 2019 was overstated by 82 %. BD is paying 175 million USD and must appoint an independent compliance consultant.
Product and approval problems are capital market issues: quality and regulatory affairs departments must be involved in the disclosure process.
- Authority / court
- U.S. Securities and Exchange Commission (SEC)
- Area of law
- Capital markets and financial supervision · Disclosure and reporting obligations
- Legal basis
- Antifraud-, Reporting-, Buchführungs-, interne Kontroll- und Disclosure-Controls-Vorschriften der US-Wertpapiergesetze
- Action
- Fine
- Status of proceedings
- final
- Sector
- Healthcare
Original amount 175,000,000 USD, converted at the ECB reference rate of 16 Dec 2024.
- Becton Dickinson to Pay $175 Million for Misleading Investors About Alaris Infusion Pump Press release of an authority
Checked against the official source on 28 Sep 2026 · Version 2 · Direct link